21st June 2023

Management

The management of malignant SVCO is dependent on the severity of the symptoms and the underlying biology of the malignancy. In those patients presenting in extremis, urgent SVC stenting should be sought via Interventional Radiology. It may be possible for a tissue diagnosis to be obtained at the same time. In patients who present with mild-moderate symptoms, the management should be tissue-directed. In those patients with known chemosensitive disease e.g. small cell lung cancer, germ-cell etc, early chemotherapy may be the treatment of choice. In those patients with less sensitive disease, exploration of SVC stenting should be sought in the first instance and where this is not possible, palliative radiotherapy should be considered.

The use of glucocorticoid steroids is not evidence-based but is commonly employed. They can be used for steroid-responsive conditions such as lymphoma or concurrently with radiotherapy. However, in patients with mild-moderate symptoms it is important to remember that in those patients lacking a tissue diagnosis, a biopsy should be prioritised. This is particularly relevant in the case of suspected lymphoma, where early administration of steroids will provide a rapid clinical response, at the expense of obtaining a tissue diagnosis. This would ultimately lead to delays in diagnosis and subsequent definitive management. The concurrent use of anticoagulation should be employed in patients with confirmed thrombosis, however, prophylactic use is debated and so no consensus statement can be offered on its empirical use.